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Mitral regurgitation (MR) is increasingly prevalent in 
western countries despite reduced incidence of rheumatic 
disease (1,2). MR results from several heterogeneous 
conditions, including disorders of the valve leaflets, mitral 
annulus, chordae tendineae, papillary muscles and left 
ventricle (LV). MR causes are roughly classified as primary 
(i.e. organic/structural) or secondary (i.e. functional/non-
structural) (3).
Degenerative disease is the most common cause of 
primary MR that often necessitates surgery. It involves 
mitral valve prolapse (Carpentier’s classification type II) and 
covers a large spectrum of lesions (isolated scallop to multi-
segment prolapse). Prolapse location, valvular/annular 
calcifications, and severity of annulus dilatation may affect 
the feasibility and choice of surgical/percutaneous repair 
techniques (4). Chronic severe primary MR leads to LV 
volume overload, which is accompanied by a progressive 
LV and left atrial remodelling, gradual rise in pulmonary 
arterial pressure, and a significant right atrial annular 
dilatation (5,6). 
Treatment decisions in primary MR are typically based 
upon symptomatic status, and resting imaging determination 
of its aetiology, severity, and consequences (1,2). Surgery is 
recommended in patients who are symptomatic at rest or 
during exercise testing (class IB). In asymptomatic patients, 
pre-operative resting LV ejection fraction <60% (ESC IC, 
AHA/ACC IB), end-systolic diameter >40 mm (AHA/ACC 
IIaB) >45 mm (ESC IIaC), recurrent atrial fibrillation, or 
pulmonary artery systolic pressure (PASP) >50 mmHg 
(ESC IIaC, AHA/ACC IIaB) represent common indications 
for mitral valve surgery, preferably repair. Surgery may be 
considered in asymptomatic patients with preserved LV 
function, high likelihood of durable repair, low surgical risk, 
and pulmonary hypertension on exercise (SPAP ≥60 mmHg 
at exercise) (ESC IIbC). 
The development of surgical mitral valve repair, 
introduced in the early seventies by Alain Carpentier, 
has dramatically changed the prognosis and management 
of patients presenting with severe primary MR (7). 
Reconstructive surgery has progressively become the 
reference in the treatment of degenerative MR due to 
the low incidence of valve-related complications (i.e., 
endocarditis, thromboembolic/bleeding events) and 
the positive effect on life expectancy (8). However, the 
success of the intervention depends on additional factors, 
including surgeon’s skill, and severity of valve lesions. 
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Indeed, recurrence of MR is far from exceptional; it is a 
recognized morbidity owning to both procedural failures 
and continuing degenerative process (9). Recurrent MR 
is reported as one of the most frequent conditions for 
mitral valve reoperation following repair. In most cases 
of reoperation (>50%), mitral valve replacement with a 
prosthetic valve needs to be performed due to advanced 
progression of the degenerative disease. According to 
published literature, the global percentage of patients 
undergoing mitral valve reoperation for any reason ranges 
from 0.7% to 10.5% (median 2.5%); however, the time 
before reoperation remains unclear. Freedom from mitral 
valve reoperation at 1-year and 5-year is typically reported 
as >94% (9).
A wide variety of surgical approaches for mitral valve 
repair are available, which aim at restoring natural 
leaflet motion, while preserving a large valve opening 
with leaflets that fit well together (10). Recent studies 
have demonstrated that the techniques which “respect 
(anatomical re-arrangement of tissues) rather than resect” 
the diseased portion of the mitral valve have comparable 
clinical outcomes, and are potentially more efficient 
to maintain mitral valve dynamics (11). During the 
last few decades, replacement of chords with expanded 
polytetrafluoroethylene (ePTFE) sutures has become a 
standard tool in reconstructive mitral surgery, both by 
standard and minimally invasive approaches (12). Indeed, 
this strategy is preferred to chordal shortening or chordal 
transfer, which has not always led to predictable and durable 
results (13,14). Artificial chordae couple the mitral valve 
and LV, and restore anatomical mitral valve structure and 
function by retaining the tension between the valve leaflet 
and the subvalvular apparatus. Replacement of chords is a 
safe and effective means of correcting anterior or posterior 
mitral valve prolapse with good long-term results. The 
extensive use of artificial chordae in cases of complex lesions 
involving the anterior or the two leaflets allows mitral 
valve repair in more than 95% of cases (15). Moreover, this 
approach could limit or avoid leaflet resection in extensive 
posterior mitral valve prolapse, which could be unamenable 
to conventional resecting repair strategies. In a recent 
randomized controlled trial, the use of loop neo-chords for 
correcting posterior mitral valve prolapse resulted in similar 
clinical and echocardiographic outcomes, but greater line 
of coaptation, as compared to conventional leaflet resection 
techniques (16). Until recently, replacement of chords has 
required open-heart surgery with bypass to stop the heart 
during the procedure (17). 
Transapical beating-heart mitral valve repair has been 
freshly introduced to treat MR while potentially reducing 
surgical morbidity. The NeoChord DS1000 has been the 
first device to be clinically approved for mitral valve repair 
by implantation of neo-chordae in patients presenting 
with degenerative MR (prolapse or flail). The system is 
introduced through the lowest part of the beating heart 
(lateral to apex), into the LV, and between the mitral valve 
leaflets. The prolapsed leaflet is then grasped, and, when 
adequately captured, the ePTFE suture is deployed and 
attached to the leaflet (Figure 1). The suture is then pulled 
through the apex of the heart as the DS1000 is removed. 
The correct length of the suture is determined by observing 
the improvement in MR in the beating heart. Early results 
from the Transapical Artificial Chordae Tendinae (TACT) 
trial demonstrated acute procedural success in 26 of the 
30 patients, with only 17 patients with <2+ grade MR at 
30 days (19) (Table 1). About 20% of the patients underwent 
reoperation for a failed repair and 16.7% of the patients 
required greater than 2 units of blood transfusion for 
blood loss at the catheter entry site in the ventricular apex. 
During the course of the study, 2 procedural refinements 
were introduced, including the revision of the LV access 
to postero-lateral approach (reduction of mechanical 
stress due to the posterolateral fixation of neo-chordae) 
and the use of multiple neo-chordae per procedure (better 
distribution of mechanical stress on leaflet tissue) (19). 
Subsequent studies showed high feasibility and confirmed 
good safety. The procedure success was related to mitral 
valve anatomy, and was less evident in anterior, bileaflet, or 
peri-commissural disease. A recent post-market surveillance 
registry conducted at 7 European centres has completed 
the enrolment of 126 patients with severe degenerative 
MR. Data from 2 of these centres confirmed initial results 
and persistent short-term efficacy with significant clinical 
benefit for the patients (20-22).
Harpoon TSD-5 is in the same category as “NeoChord” 
and is designed to facilitate beating-heart minimally 
invasive echo-guided mitral valve repair. It is approved 
for degenerative MR. A key feature of the system is that it 
automates a critical part of the repair process, simplifying 
the procedure and reducing its duration. In this device, a 
pre-formed ePTFE knot is deployed on the atrial surface 
of the prolapsing or flail mitral leaflet, away from the leaflet 
edge, and towards the belly (Figure 1). Compared with the 
Neochord device, the Harpoon device is characterized by 
a smaller-diameter shaft (3 vs. 8 mm), a valved introducer 
to minimize intraprocedural bleeding, the ability to insert 
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the ePTFE cords anywhere on the leaflet rather than 
within 4 mm of the free edge, and a fundamentally different 
anchoring mechanism. Gammie et al. recently reported 
the results of the first safety study of the device. This study 
involved a total of 11 patients with severe degenerative 
MR resulting from isolated posterior leaflet prolapse who 
underwent the procedure at two facilities in Poland. The 
authors reported a 100% procedural success rate with stable 
results after 30 days. An average of 3.6±0.7 (range 3–5) pairs 
of ePTFE artificial cords were implanted, with reduction 
of MR during the procedure from severe to none/trace in 
8 patients and to mild in 3 patients. Total procedure time 
averaged 108±30 minutes (range, 72–167 minutes). The 
procedure was safe with no acute conversions to open-
heart surgery, blood transfusions, stroke, or death. MR 
reduction was stable in the 3 of 4 patients followed-up to 
6 months (23). Of note, there was some progression of MR 
from no patients having moderate MR and 3 with mild MR 
at the end of the procedure to 2 moderate and 5 mild MR at 
30 days.
The benefits of mitral valve repair over replacement are 
indisputable and the trend towards more repair techniques 
in MR is predicted to continue. The most straightforward 
application of transapical beating-heart artificial chordae 
implantation concerns the case of isolated prolapse of a 
single mitral valve leaflet due to degenerative disease with 
limited mitral annulus dilatation and LV remodelling. 
Often two or more chordae are necessary to get good 
MR reduction. These transapical approaches have some 
advantages because they simplify the procedure, they 
preserve the subvalvular apparatus, and they facilitate 
both implantation and tension adjustment (as the heart 
is fully loaded and beating) of the neo-chordae under 
transesophageal echocardiographic guidance. However, 
the disadvantage of the technique is that it creates neo-
chordae with a fixed length, which relies solely on 
echocardiographic evaluation. Indeed, minor errors in 
chordae length can have dramatic consequences on the 
tension of the chordae (18). The chordae are more than 
simple connections between the papillary muscles and 
the mitral annulus. Variations in the length of individual 
chordae modulate overall chordae tension, the coaptation 
Figure 1 Transapical beating-heart mitral valve repair using artificial chorrdae implantation. (A) Neo-Chord DS1000 with artificial chordae 
attachment at the edge of the leaflet, (B) Harpoon TSD-5 with artificial chordae attachment at the belly of the leaflet (last image shows 
endothelial ingrowth of 2 expanded polytetrafluoroethylene knots on the atrial surface of the posterior leaflet). Image partially reproduced 
from publicly available information on NeoChord Website and from Gammie et al. (18).
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area of the mitral leaflets and mitral hemodynamics 
especially in the absence of remodelling annuloplasty whose 
role in evenly distributing constraints along the mitral valve 
complex is well documented (24). Chordae that are longer 
than normal do not make the mitral valve incompetent, but 
can increase adjacent chordae tension, while using shorter-
than-normal chordae can produce stress concentrations 
at both ends of the neo-chordae. At the free edge of the 
leaflet this can impair proper mitral valve closure or lead 
to dehiscence at the anchoring site. Increased tensile stress 
on the PTFE chords can also possibly facilitate subsequent 
rupture (25). Mechanical stress in traction close to the base 
of the papillary muscle can trigger by different mechanisms 
arrhythmias as observed in some forms of mitral valve 
prolapse (5). These reasonable Speculations/hypotheses 
emphasize the “a priori” critical impact of length adjustment 
and related forces applied to the mitral valve apparatus 
on the outcome. A potential drawback of the Neo-Chord 
DS1000 is its limited ability to restore coaptation along the 
entire flailing/prolapsing edge. Conversely, the Harpoon 
TSD-5, by supporting the leaflet belly, may be sufficient 
to parallelize the leaflet with the non-prolapsing leaflet, 
and achieve leaflet coaptation. However, this is purely 
hypothetical and whether the system can realize a better 
positioning remains unclear. Nevertheless, it is likely that 
a positioning further away from the edge of the leaflet 
should reduce the amount of tissue available for coaptation. 
The pre-formed knot may potentially overcome the 
shortcomings of focal NeoChord loop deployment (zone 
of focal stress), and supports a larger region (no inter-loop 
persisting prolapse) of the leaflet with a single neo-chord. 
A key advantage of the Neo-Chord remains, however, the 
possibility to be removed prior to the creation of the knot, 
while the Harpoon’s cords cannot be removed once fired. 
Transcatheter mitral valve repair technologies have 
progressively gained widespread interest, and have widely 
been adopted. Transapical beating-heart artificial chordae 
implantation represents an additional approach to the 
current options for mitral valve repair, and will likely 
become an important component of the mitral valve 
surgeon’s armamentarium. Conversely, transfemoral 
approach (i.e., MitraClip) will certainly remain the 
preferred option of interventional cardiologists. With the 
possibility of using the Neo-Chord DS1000 or the Harpoon 
TSD-5 in both high and low risk patients, the level of 
repair perfection remains very high given the excellent 
results of conventional surgery. However, while promising, 
the routine use of such novel technology requires additional 
experience and a better understanding of the following 
aspects: learning curve, exact positioning of the neo-
chordae to the prolapsing segment; length adjustment 
of the neo-chord to eliminate prolapse; prevention of 
leaflet restriction; impact of apical fixations on mitral valve 
structure and function (higher rate of change of force in the 
chord as compared to papillary muscles insertion); possible 
injury of mitral valve leaflets/chordae tendineae; risk of MR 
progression/recurrence without concomitant annuloplasty, 
interest of combined transcatheter techniques (i.e., the 
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